Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03568994 · ClinicalTrials.gov registry record · Early Phase 1
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)
A Early Phase 1 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
NCT03568994 is a Early Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 26 participants.
The verdict
NCT03568994, a Early Phase 1 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study will test daily dosing of atovaquone at established pneumocystis jiroveci pneumonia (PJP) prophylaxis dosing in combination with standard induction chemotherapy for de novo AML. The primary objectives are to determine the frequency of omission of atovaquone doses due to standard induction chemotherapy toxicity, to quantify the steady-state plasma levels of atovaquone, and to determine the time to achievement of steady state atovaquone levels in this population.
Interventions
- DRUG Gemtuzumab Ozogamicin
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG Atovaquone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-07-10 |
| Est. Completion | 2025-09-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03568994
The ClinicalTrials.gov registry entry for NCT03568994 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Gemtuzumab Ozogamicin is the first listed.
NCT03568994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03568994 about?
NCT03568994 is a clinical study titled "Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)". This study will test daily dosing of atovaquone at established pneumocystis jiroveci pneumonia (PJP) prophylaxis dosing in combination with standard induction chemotherapy for de novo AML. The primary objectives are to determine the frequency of omission of atovaquone doses due to standard induction...
What is the current status of trial NCT03568994?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2018-07-10. Estimated completion is 2025-09-20.
What interventions are being tested in trial NCT03568994?
The interventions under investigation include: Gemtuzumab Ozogamicin (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Daunorubicin (DRUG), Atovaquone (DRUG).
Who is sponsoring clinical trial NCT03568994?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.